{"id":"NCT03587805","sponsor":"LEO Pharma","briefTitle":"Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND","officialTitle":"An Open-label, Single-arm, Multi-centre, Long-term Extension Trial to Evaluate the Safety and Efficacy of Tralokinumab in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Clinical Trials","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-03-18","primaryCompletion":"2024-07-03","completion":"2024-07-03","firstPosted":"2018-07-16","resultsPosted":"2025-01-16","lastUpdate":"2025-03-11"},"enrollment":1672,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"Tralokinumab","otherNames":[]}],"arms":[{"label":"Tralokinumab, all subjects","type":"EXPERIMENTAL"}],"summary":"The purpose of this extension trial is to evaluate the long-term safety of tralokinumab.","primaryOutcome":{"measure":"Number of Adverse Events From Baseline Through the Last Treatment Visit (up to Week 268)","timeFrame":"From Week 0 up to Week 268","effectByArm":[{"arm":"Tralokinumab, All Subjects","deltaMin":8119,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":10},"locations":{"siteCount":309,"countries":["United States","Belgium","Canada","Czechia","France","Germany","Italy","Japan","Poland","Spain","United Kingdom"]},"refs":{"pmids":["35863467","38563683","36223087","40879371","40085349"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":151,"n":1672},"commonTop":["Nasopharyngitis","Atopic dermatitis","Covid-19","Upper respiratory tract infection","Headache"]}}